Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Pacira BioSciences stock | $52.11

Learn how to easily invest in Pacira BioSciences stock.

Pacira BioSciences Inc is a drug manufacturers-specialty & generic business based in the US. Pacira BioSciences shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pacira BioSciences employs 624 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Pacira BioSciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PCRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pacira BioSciences stock price (NASDAQ: PCRX)

Use our graph to track the performance of PCRX stocks over time.

Pacira BioSciences shares at a glance

Information last updated 2021-10-10.
Latest market close$52.11
52-week range$47.54 - $80.00
50-day moving average $55.97
200-day moving average $60.42
Wall St. target price$78.07
PE ratio 12.4533
Dividend yield N/A (0%)
Earnings per share (TTM) $3.85

Buy Pacira BioSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pacira BioSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pacira BioSciences price performance over time

Historical closes compared with the close of $52.11 from 2021-10-13

1 week (2021-10-08) 8.63%
1 month (2021-09-15) -5.56%
3 months (2021-07-15) -7.06%
6 months (2021-04-15) -21.45%
1 year (2020-10-15) -10.25%
2 years (2019-10-15) 36.77%
3 years (2018-10-15) 14.98%
5 years (2016-10-14) 57.01%

Is Pacira BioSciences under- or over-valued?

Valuing Pacira BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacira BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pacira BioSciences's P/E ratio

Pacira BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Pacira BioSciences shares trade at around 12x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Pacira BioSciences's EBITDA

Pacira BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $122.1 million.

The EBITDA is a measure of a Pacira BioSciences's overall financial performance and is widely used to measure a its profitability.

Pacira BioSciences financials

Revenue TTM $503.1 million
Operating margin TTM 20.33%
Gross profit TTM $252.9 million
Return on assets TTM 5.83%
Return on equity TTM 32.38%
Profit margin 34.6%
Book value $15.46
Market capitalisation $2.1 billion

TTM: trailing 12 months

Shorting Pacira BioSciences shares

There are currently 7.2 million Pacira BioSciences shares held short by investors – that's known as Pacira BioSciences's "short interest". This figure is 5.7% up from 6.8 million last month.

There are a few different ways that this level of interest in shorting Pacira BioSciences shares can be evaluated.

Pacira BioSciences's "short interest ratio" (SIR)

Pacira BioSciences's "short interest ratio" (SIR) is the quantity of Pacira BioSciences shares currently shorted divided by the average quantity of Pacira BioSciences shares traded daily (recently around 353792.44071146). Pacira BioSciences's SIR currently stands at 20.24. In other words for every 100,000 Pacira BioSciences shares traded daily on the market, roughly 20240 shares are currently held short.

However Pacira BioSciences's short interest can also be evaluated against the total number of Pacira BioSciences shares, or, against the total number of tradable Pacira BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pacira BioSciences's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Pacira BioSciences shares in existence, roughly 160 shares are currently held short) or 0.1625% of the tradable shares (for every 100,000 tradable Pacira BioSciences shares, roughly 163 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Pacira BioSciences.

Find out more about how you can short Pacira BioSciences stock.

Pacira BioSciences share dividends

We're not expecting Pacira BioSciences to pay a dividend over the next 12 months.

Pacira BioSciences share price volatility

Over the last 12 months, Pacira BioSciences's shares have ranged in value from as little as $47.54 up to $80. A popular way to gauge a stock's volatility is its "beta".

PCRX.US volatility(beta: 1.05)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira BioSciences's is 1.0487. This would suggest that Pacira BioSciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Pacira BioSciences overview

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.

Frequently asked questions

What percentage of Pacira BioSciences is owned by insiders or institutions?
Currently 0.89% of Pacira BioSciences shares are held by insiders and 115.35% by institutions.
How many people work for Pacira BioSciences?
Latest data suggests 624 work at Pacira BioSciences.
When does the fiscal year end for Pacira BioSciences?
Pacira BioSciences's fiscal year ends in December.
Where is Pacira BioSciences based?
Pacira BioSciences's address is: 5 Sylvan Way, Parsippany, NJ, United States, 07054
What is Pacira BioSciences's ISIN number?
Pacira BioSciences's international securities identification number is: US6951271005
What is Pacira BioSciences's CUSIP number?
Pacira BioSciences's Committee on Uniform Securities Identification Procedures number is: 695127100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site